Johan Rosell1,2, Bo Nordenskjöld2, Nils-Olof Bengtsson3, Tommy Fornander4, Thomas Hatschek4, Henrik Lindman5, Per-Olof Malmström6, Arne Wallgren7, Olle Stål2, John Carstensen8. 1. a Regional Cancer Center South East Sweden , Linköping , Sweden. 2. b Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences , Linköping University , Linköping , Sweden. 3. c Department of Oncology , Umeå University Hospital , Umeå , Sweden. 4. d Department of Oncology , Karolinska University Hospital , Stockholm , Sweden. 5. e Department of Oncology , Uppsala University Hospital , Uppsala , Sweden. 6. f Skånes Department of Oncology , Skåne University Hospital , Lund , Sweden. 7. g Department of Oncology , Sahlgrenska University Hospital , Göteborg , Sweden. 8. h Department of Medical and Health Sciences , Linköping University , Linköping , Sweden.
Abstract
BACKGROUND:Tamoxifen is a well established treatment for breast cancer, but its long-term effects on the incidence of secondary cancers are not fully evaluated. MATERIAL AND METHODS: We have studied 4128 postmenopausal patients with early stage breast cancer who were alive and free of breast cancer recurrence after two years oftamoxifen, and who were randomized to receive totally two or five years of therapy. RESULTS: Compared to patients randomized to two years of tamoxifen the incidence of contralateral breast cancer [hazard ratio (HR) 0.73; 95% CI 0.56-0.96] and of lung cancer (HR 0.45; 95% CI 0.27-0.77), especially squamous cell and small cell lung cancer, were reduced in the five-year group, and similar results were seen when restricting the analysis to the 10-year period after treatment stopped. An increased incidence of endometrial cancer was observed in the five-year group, but the excess risk decreased over time. CONCLUSION: Further studies of the effects of tamoxifen on the risk of different histological types of lung cancer are needed.
RCT Entities:
BACKGROUND:Tamoxifen is a well established treatment for breast cancer, but its long-term effects on the incidence of secondary cancers are not fully evaluated. MATERIAL AND METHODS: We have studied 4128 postmenopausal patients with early stage breast cancer who were alive and free of breast cancer recurrence after two years of tamoxifen, and who were randomized to receive totally two or five years of therapy. RESULTS: Compared to patients randomized to two years of tamoxifen the incidence of contralateral breast cancer [hazard ratio (HR) 0.73; 95% CI 0.56-0.96] and of lung cancer (HR 0.45; 95% CI 0.27-0.77), especially squamous cell and small cell lung cancer, were reduced in the five-year group, and similar results were seen when restricting the analysis to the 10-year period after treatment stopped. An increased incidence of endometrial cancer was observed in the five-year group, but the excess risk decreased over time. CONCLUSION: Further studies of the effects of tamoxifen on the risk of different histological types of lung cancer are needed.
Authors: Patricia A Young; Diana C Márquez-Garbán; Zorawar Singh Noor; Neda Moatamed; David Elashoff; Tristan Grogan; Tahmineh Romero; Hironobu Sasano; Ryoko Saito; Rebecca Rausch; Nalo Hamilton; Steven M Dubinett; Edward B Garon; Richard J Pietras Journal: JTO Clin Res Rep Date: 2021-02-03
Authors: Anna-Karin Wennstig; Charlotta Wadsten; Hans Garmo; Mikael Johansson; Irma Fredriksson; Carl Blomqvist; Lars Holmberg; Greger Nilsson; Malin Sund Journal: NPJ Breast Cancer Date: 2021-06-01
Authors: Tamar B Nobel; Rebecca A Carr; Raul Caso; Jennifer Livschitz; Samuel Nussenzweig; Meier Hsu; Kay See Tan; Smita Sihag; Prasad S Adusumilli; Matthew J Bott; Robert J Downey; James Huang; James M Isbell; Bernard J Park; Gaetano Rocco; Valerie W Rusch; David R Jones; Daniela Molena Journal: BJS Open Date: 2021-11-09